0	19	Platelet-activating	platelet-activating	JJ
20	26	factor	factor	NN
27	28	(	(	(
28	31	PAF	PAF	NNP
31	32	)	)	)
33	43	positively	positively	RB
44	58	auto-regulates	auto-regulate	VBZ
59	62	the	the	DT
63	73	expression	expression	NN
74	76	of	of	IN
77	82	human	human	JJ
83	86	PAF	PAF	NNP
87	95	receptor	receptor	NN
96	106	transcript	transcript	NN
107	108	1	1	CD
109	110	(	(	(
110	124	leukocyte-type	leukocyte-type	NN
124	125	)	)	)
126	133	through	through	IN
134	142	NF-kappa	NF-kappa	NNP
143	145	B.	B.	NNP
147	150	The	the	DT
151	156	human	human	JJ
157	176	platelet-activating	platelet-activating	JJ
177	183	factor	factor	NN
184	192	receptor	receptor	NN
193	194	(	(	(
194	198	PAFR	PAFR	NNP
198	199	)	)	)
200	204	gene	gene	NN
205	207	is	be	VBZ
208	219	transcribed	transcribe	VBN
220	222	by	by	IN
223	226	two	two	CD
227	235	distinct	distinct	JJ
236	245	promoters	promoter	NNS
246	247	(	(	(
247	255	promoter	promoter	NN
256	257	1	1	CD
258	261	and	and	CC
262	270	promoter	promoter	NN
271	272	2	2	CD
272	273	)	)	)
274	276	to	to	TO
277	285	generate	generate	VB
286	289	two	two	CD
290	301	transcripts	transcript	NNS
302	303	(	(	(
303	313	designated	designate	VBN
314	316	as	as	IN
317	321	PAFR	PAFR	NNP
322	332	transcript	transcript	NN
333	334	1	1	CD
335	338	and	and	CC
339	343	PAFR	pafr	NN
344	354	transcript	transcript	NN
355	356	2	2	CD
356	357	)	)	)
357	358	,	,	,
359	365	though	though	IN
366	371	their	their	PRP$
372	376	open	open	JJ
377	384	reading	reading	NN
385	391	frames	frame	NNS
392	395	are	be	VBP
396	405	identical	identical	JJ
405	406	.	.	.

407	409	By	by	IN
410	416	primer	primer	NN
417	426	extension	extension	NN
427	435	analysis	analysis	NN
436	438	to	to	TO
439	451	discriminate	discriminate	VB
452	455	two	two	CD
456	467	transcripts	transcript	NNS
467	468	,	,	,
469	471	we	we	PRP
472	477	found	find	VBD
478	482	that	that	IN
483	486	the	the	DT
487	493	levels	level	NNS
494	496	of	of	IN
497	501	PAFR	PAFR	NNP
502	512	transcript	transcript	NN
513	514	1	1	CD
515	516	(	(	(
516	530	leukocyte-type	leukocyte-type	NN
530	531	)	)	)
531	532	,	,	,
533	536	but	but	CC
537	540	not	not	RB
541	545	PAFR	pafr	NN
546	556	transcript	transcript	NN
557	558	2	2	CD
559	560	(	(	(
560	571	tissue-type	tissue-type	NN
571	572	)	)	)
572	573	,	,	,
574	577	are	be	VBP
578	589	upregulated	upregulate	VBN
590	592	by	by	IN
593	596	PAF	PAF	NNP
597	599	as	as	RB
600	604	well	well	RB
605	607	as	as	IN
608	610	by	by	IN
611	647	12-O-tetradecanoylphorbol-13-acetate	12-O-tetradecanoylphorbol-13-acetate	NNP
648	649	(	(	(
649	652	TPA	TPA	NNP
652	653	)	)	)
654	656	in	in	IN
657	660	the	the	DT
661	666	human	human	JJ
667	674	stomach	stomach	NN
675	681	cancer	cancer	NN
682	686	cell	cell	NN
687	691	line	line	NN
692	693	(	(	(
693	698	JR-St	jr-st	JJ
699	704	cells	cell	NNS
704	705	)	)	)
706	711	which	which	WDT
712	721	expresses	express	VBZ
722	726	both	both	CC
727	737	functional	functional	JJ
738	742	PAFR	pafr	NN
743	753	transcript	transcript	NN
754	755	1	1	CD
756	759	and	and	CC
760	764	PAFR	pafr	NN
765	775	transcript	transcript	NN
776	777	2	2	CD
778	790	endogenously	endogenously	RB
790	791	.	.	.

792	802	Functional	functional	JJ
803	811	analysis	analysis	NN
812	814	of	of	IN
815	818	the	the	DT
819	827	promoter	promoter	NN
828	829	1	1	CD
830	834	with	with	IN
835	836	a	a	DT
837	846	transient	transient	JJ
847	857	expression	expression	NN
858	863	assay	assay	NN
864	869	using	use	VBG
870	885	chloramphenicol	chloramphenicol	NN
886	903	acetyltransferase	acetyltransferase	NN
904	905	(	(	(
905	908	CAT	CAT	NNP
908	909	)	)	)
910	914	gene	gene	NN
915	917	as	as	IN
918	919	a	a	DT
920	928	reporter	reporter	NN
929	935	showed	show	VBD
936	940	that	that	IN
941	945	both	both	CC
946	949	PAF	PAF	NNP
950	953	and	and	CC
954	957	TPA	TPA	NNP
958	967	activated	activate	VBD
968	971	the	the	DT
972	980	promoter	promoter	NN
981	982	1	1	CD
983	986	but	but	CC
987	990	not	not	RB
991	994	the	the	DT
995	1002	deleted	delete	VBN
1003	1011	promoter	promoter	NN
1012	1019	lacking	lack	VBG
1020	1023	the	the	DT
1024	1029	three	three	CD
1030	1039	consensus	consensus	NN
1040	1047	binding	binding	NN
1048	1053	sites	site	NNS
1054	1057	for	for	IN
1058	1066	NF-kappa	NF-kappa	NNP
1067	1068	B	B	NNP
1069	1076	located	located	JJ
1077	1081	from	from	IN
1082	1086	-571	-571	CD
1087	1089	bp	bp	NN
1090	1092	to	to	TO
1093	1097	-459	-459	CD
1098	1100	bp	bp	NN
1100	1101	.	.	.

1102	1107	These	these	DT
1108	1116	findings	finding	NNS
1117	1124	suggest	suggest	VBP
1125	1126	a	a	DT
1127	1136	molecular	molecular	JJ
1137	1146	mechanism	mechanism	NN
1147	1149	of	of	IN
1150	1158	positive	positive	JJ
1159	1169	regulation	regulation	NN
1170	1172	of	of	IN
1173	1177	PAFR	PAFR	NNP
1178	1182	gene	gene	NN
1183	1193	expression	expression	NN
1194	1196	by	by	IN
1197	1200	PAF	PAF	NNP
1201	1208	through	through	IN
1209	1217	NF-kappa	NF-kappa	NNP
1218	1219	B	B	NNP
1219	1220	,	,	,
1221	1229	possibly	possibly	RB
1230	1232	by	by	IN
1233	1234	a	a	DT
1235	1250	phosphorylation	phosphorylation	NN
1251	1259	reaction	reaction	NN
1260	1269	involving	involve	VBG
1270	1277	protein	protein	NN
1278	1284	kinase	kinase	NNP
1285	1286	C	C	NNP
1287	1289	by	by	IN
1290	1293	PAF	PAF	NNP
1293	1294	.	.	.